New pill could clear psoriasis skin in weeks

NCT ID NCT07150988

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests an oral drug called HSK44459 for adults with moderate to severe plaque psoriasis. About 150 participants will receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug can reduce psoriasis skin symptoms by at least 75%.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
HSK44459 (oral drug)
What this could lead to
If successful, this could lead to a new oral treatment option for people with moderate to severe plaque psoriasis, helping clear skin symptoms.
What could go wrong
This is an early phase 2 trial with only 150 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hangzhou First People's Hospital

    Hangzhou, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.